METHODS FOR THE PREVENTION OF CHOLESTEROL CRYSTAL EMBOLIZATION WITH CYCLODEXTRINS
Disclosed herein are methods for preventing or reducing the risk of developing, and/or preventing or reducing the risk of an increase in an amount of and/or a size of, and/or changing the shape of, circulating (e.g., blood, serum, plasma) cholesterol crystals (and/or clots comprising cholesterol crystals) in an individual. Further disclosed herein are methods of preventing or reducing the risk of cholesterol crystal embolization (CCE) and/or a symptom thereof in an individual. The methods generally involve administering a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin to the individual. Further provided herein are pharmaceutical compositions comprising a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin and a pharmaceutically acceptable excipient.
1 . A method for reducing the risk of or preventing cholesterol crystal embolization (CCE) or a symptom thereof in an individual at risk for developing CCE, the method comprising administering to the individual a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin.
2 . A method for preventing an increase in an amount and/or size of circulating cholesterol crystals and/or clots comprising cholesterol crystals in an individual, the method comprising administering a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin to the individual, thereby preventing an increase in the amount or size of circulating cholesterol crystals and/or clots comprising cholesterol crystals in the individual by greater than 100% relative to the amount or size of circulating cholesterol crystals and/or clots comprising cholesterol crystals prior to administration of the 2-hydroxypropyl-beta-cyclodextrin and/or prior to vascular/cardiovascular trauma.
3 . The method of claim 2 , wherein the individual is an individual at risk for an increase in the amount of circulating cholesterol crystals and/or clots comprising cholesterol crystals, for an increase in the size of circulating cholesterol crystals and/or clots comprising cholesterol crystals, and/or for developing a cholesterol crystal embolization (CCE).
4 . The method of any one of the preceding claims, wherein the individual has previously experienced a cholesterol crystal embolization (CCE).
5 . The method of any one of the preceding claims, wherein the individual is undergoing, is scheduled to undergo, or has experienced a vascular or cardiovascular trauma.
6 . The method of claim 5 , wherein the vascular or cardiovascular trauma is selected from the group consisting of: an interventional vascular procedure, a diagnostic vascular procedure, a vascular access procedure, cardiovascular surgery, a cardiovascular injury, and any combination thereof.
7 . The method of any one of the preceding claims, wherein the individual is male, a smoker, more than 50 years old, or any combination thereof.
8 . The method of any one of the preceding claims, wherein the individual suffers from, has been diagnosed with, or has suffered from a coagulation disorder, aortic aneurysm, cardiovascular disease, aortic plaque, hypertension, diabetes mellitus, hyperlipidemia, increased inflammation (e.g., as determined by increased serum CRP levels), or any combination thereof.
9 . The method of any one of the preceding claims, wherein the individual is undergoing or has undergone a therapy associated with increased risk of cholesterol crystal embolization (CCE).
10 . The method of any one of the preceding claims, wherein the individual is undergoing anticoagulation or thrombolytic therapy.
11 . A method for reducing the risk of or preventing cholesterol crystal embolization (CCE) in an individual or preventing an increase in the amount and/or size of, and/or changing the shape of, circulating cholesterol crystals and/or clots comprising cholesterol crystals in an individual, the method comprising:
(a) administering a therapeutically effective amount of 2-hydroxypropyl-beta-cyclodextrin to the individual; and
(b) subjecting the individual to a vascular or cardiovascular trauma.
12 . The method of any one of the preceding claims, wherein an increase in the amount of or size of circulating cholesterol crystals and/or clots comprising cholesterol crystals in the individual by greater than 100% relative to the amount and/or size of circulating cholesterol crystals and/or clots comprising cholesterol crystals prior to administration of the 2-hydroxypropyl-beta-cyclodextrin and/or prior to vascular/cardiovascular trauma is prevented.
13 . The method of any one of the preceding claims, wherein an increase in the amount of or size of circulating cholesterol crystals in the individual by greater than 50% relative to the amount and/or size of circulating cholesterol crystals prior to administration of the 2-hydroxypropyl-beta-cyclodextrin and/or prior to vascular/cardiovascular trauma is prevented.
14 . The method of any one of the preceding claims, wherein an increase in the amount of or size of circulating cholesterol crystals and/or clots comprising cholesterol crystals in the individual by greater than 30% relative to the amount and/or size of circulating cholesterol crystals and/or clots comprising cholesterol crystals prior to administration of the 2-hydroxypropyl-beta-cyclodextrin and/or prior to vascular/cardiovascular trauma is prevented.
15 . The method of any one of the preceding claims, wherein an increase in the amount of or size of circulating cholesterol crystals and/or clots comprising cholesterol crystals in the individual by greater than 15% relative to the amount and/or size of circulating cholesterol crystals and/or clots comprising cholesterol crystals prior to administration of the 2-hydroxypropyl-beta-cyclodextrin and/or prior to vascular/cardiovascular trauma is prevented.
16 . The method of any one of the preceding claims, wherein an increase in the amount of or size of circulating cholesterol crystals and/or clots comprising cholesterol crystals in the individual by greater than 5% relative to the amount and/or size of circulating cholesterol crystals and/or clots comprising cholesterol crystals prior to administration of the 2-hydroxypropyl-beta-cyclodextrin and/or prior to vascular/cardiovascular trauma is prevented.
17 . The method of any one of the preceding claims, wherein an increase in the amount of and/or size of circulating cholesterol crystals and/or clots comprising cholesterol crystals in the individual relative to the amount and/or size of circulating cholesterol crystals and/or clots comprising cholesterol crystals prior to administration of the 2-hydroxypropyl-beta-cyclodextrin or prior to vascular/cardiovascular trauma is prevented.
18 . The method of any one of the preceding claims, wherein the therapeutically effective amount is from about 50 mg/kg to about 2000 mg/kg.
19 . The method of any one of the preceding claims, wherein the therapeutically effective amount is from about 4 g to about 250 g.
20 . The method of any one of the preceding claims, wherein the therapeutically effective amount is an amount sufficient to achieve a serum, plasma, and/or whole blood concentration of 2-hydroxypropyl-beta-cyclodextrin of about 0.01 mM to about 3 mM.
21 . The method of any one of the preceding claims, wherein the therapeutically effective amount is an amount effective to increase a circulating and/or systemic level of one or more oxysterol in the individual by at least about 10% after the administering as compared to prior to the administering.
22 . The method of claim 21 , wherein the one or more oxysterol is 24S-hydroxycholesterol, 27-hydroxycholesterol, or both.
23 . The method of any one of the preceding claims, wherein the therapeutically effective amount is an amount effective to plasma cholesterol crystal dissolution capacity (CCDC) by at least about 10% after the administering as compared to prior to the administering.
24 . The method of any one of the preceding claims, wherein the therapeutically effective amount is an amount effective to increase mRNA levels of ABCA1 and/or ABCG1 by at least about 10% after the administering as compared to prior to the administering.
25 . The method of any one of the preceding claims, wherein the 2-hydroxypropyl-beta-cyclodextrin is selected from the group consisting of: Kleptose® HP Parenteral Grade, Kleptose® HPB Parenteral Grade, Kleptose® HPB-LB Parenteral Grade, Cavitron® W7 HP5 Pharma cyclodextrin, Cavitron® W7 HP7 Pharma cyclodextrin, Trappsol® Cyclo™, and VTS-270/adrabetadex.
26 . The method of any one of the preceding claims, wherein the individual is a human.
27 . The method of any one of the preceding claims, wherein the administering further comprises:
(a) administering, at a first time point, a therapeutically effective first dose of 2-hydroxypropyl-beta-cyclodextrin to the individual; and
(b) administering, at a second time point, a therapeutically effective second dose of 2-hydroxypropyl-beta-cyclodextrin to the individual.
28 . The method of claim 27 , wherein the second time point is less than one month after the first time point.
29 . The method of claim 26 or 27 , wherein the second time point is at least 4 hours after the first time point.
30 . The method of any one of the preceding claims, wherein the administering is by intravenous administration.
31 . The method of any one of the preceding claims, wherein the administering further comprises administering 2-hydroxylpropyl-beta-cyclodextrin in a 12 hour period.
32 . The method of any one of the preceding claims, wherein the administering further comprises administering 2-hydroxylpropyl-beta-cyclodextrin in a 10 hour period.
33 . The method of any one of the preceding claims, wherein the administering further comprises administering 2-hydroxylpropyl-beta-cyclodextrin in an 8 hour period.
34 . The method of any one of the preceding claims, wherein the administering further comprises administering 2-hydroxylpropyl-beta-cyclodextrin in a 6 hour period.
35 . The method of any one of the preceding claims, wherein the administering further comprises:
(a) administering, at a first time point, a therapeutically effective first dose of 2-hydroxylpropyl-beta-cyclodextrin to the individual;
(b) evaluating, at a second time point, a blood serum, plasma, or whole blood concentration of 2-hydroxypropyl-beta-cyclodextrin; and
(c) administering a therapeutically effective second dose of 2-hydroxylpropyl-beta-cyclodextrin to the individual when the blood serum, plasma, or whole blood concentration is less than 0.01 mM.
36 . The method of claim 35 , wherein the second time point is within 24 hours of the first time point.
37 . A pharmaceutical composition comprising: an amount of 2-hydroxypropyl-beta-cyclodextrin effective to prevent an increase in an amount of and/or a size of circulating cholesterol crystals and/or clots comprising cholesterol crystals in an individual; and a pharmaceutically acceptable excipient.
38 . A pharmaceutical composition comprising: an amount of 2-hydroxypropyl-beta-cyclodextrin effective to reduce the risk of or prevent cholesterol crystal embolization (CCE) and/or a symptom thereof, in an individual; and a pharmaceutically acceptable excipient.
39 . The pharmaceutical composition of claim 37 or 38 , formulated for single dose administration.
40 . The pharmaceutical composition of any one of claims 37 - 39 , formulated for intravenous administration.
41 . The pharmaceutical composition of any one of claims 37 - 40 , wherein the amount of 2-hydroxypropyl-beta-cyclodextrin is an amount effective to increase a circulating and/or systemic level of one or more oxysterols in the individual by at least about 10% after administering the pharmaceutical composition to the individual.
42 . The pharmaceutical composition of claim 41 , wherein the one or more oxysterols is 24S-hydroxycholesterol, 27-hydroxycholesterol, or both.
43 . The pharmaceutical composition of any one of claims 37 - 42 , wherein the amount of 2-hydroxypropyl-beta-cyclodextrin is an amount effective to increase plasma cholesterol crystal dissolution capacity (CCDC) in the individual by at least about 10% after administering the pharmaceutical composition to the individual.
44 . The pharmaceutical composition of any one of claims 37 - 43 , wherein the amount of 2-hydroxypropyl-beta-cyclodextrin is an amount effective to increase mRNA levels of ABCA1 and/or ABCG1 in the individual by at least about 10% after administering the pharmaceutical composition to the individual.
45 . A kit comprising:
(a) one or more container; and
(b) the pharmaceutical composition of any one of claims 37 - 44 , wherein the pharmaceutical composition is contained within the one or more container.
46 . The kit of claim 45 , further comprising (c) instructions for use of the pharmaceutical composition for preventing an increase in an amount and/or size of circulating cholesterol crystals and/or clots comprising cholesterol crystals in an individual and/or for reducing the risk of or preventing cholesterol crystal embolization (CCE) or a symptom thereof in an individual at risk for developing CCE.
47 . The kit of claim 45 or 46 , wherein at least one of the one or more container is an IV infusion bag.
48 . The kit of any one of claims 45 - 47 , wherein the one or more container comprises a single container comprising the pharmaceutical composition and one or more additional active pharmaceutical ingredients.
49 . The kit of any one of claims 45 - 48 , wherein the one or more container comprises a first container containing the pharmaceutical composition and a second container containing one or more additional active pharmaceutical ingredients.
50 . The kit of any one of claims 45 - 49 , further comprising one or more additional components selected from the group consisting of: an IV infusion bag, a catheter, tubing, a needle, a syringe, a solution, and any combination thereof.